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Abstract: (1) Background. Cushing’s disease presents gender disparities in prevalence and clinical
course. Little is known, however, about sexual dimorphism at the level of the corticotrope adenoma
itself. The aim of the present study was to evaluate molecular features of ACTH-secreting pituitary
adenomas collected from female and male patients with Cushing’s disease. (2) Methods. We analyzed
153 ACTH-secreting adenomas collected from 31 men and 122 women. Adenomas were established
in culture and ACTH synthesis and secretion assessed in basal conditions as well as during incubation
with CRH or dexamethasone. Concurrently, microarray analysis was performed on formalin-fixed
specimens and differences in the expression profiles between specimens from male and female patients
identified. (3) Results. ACTH medium concentrations in adenomas obtained from male patients were
significantly lower than those observed in adenomas from female patients. This could be observed for
baseline as well as modulated secretion. Analysis of corticotrope transcriptomes revealed considerable
similarities with few, selected differences in functional annotations. Differentially expressed genes
comprised genes with known sexual dimorphism, genes involved in tumour development and genes
relevant to pituitary pathophysiology. (4) Conclusions. Our study shows for the first time that human
corticotrope adenomas present sexual dimorphism and underlines the need for a gender-dependent
analysis of these tumours. Differentially expressed genes may represent the basis for gender-tailored
target therapy.
Keywords: Cushing’s disease; gender; gene expression profiling; neuroendocrine tumours; ACTH-
secreting adenomas
1. Introduction
ACTH-secreting pituitary adenomas, i.e., Cushing’s disease, are known to occur far more
frequently in women than in men [1,2] and, as we first showed some years ago [3], give rise to a
somewhat different clinical course in the two sexes. In fact, men with Cushing’s disease are more
likely to be younger, exhibit a more severe clinical presentation and a less favourable response to
surgical as well as medical treatment [3–9]. Furthermore, recently identified somatic mutations in the
deubiquitinases USP8 and USP48 occurs with greater frequency in women than men with Cushing’s
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disease [10,11], suggesting that the corticotrope adenoma itself may harbour features which contribute
to gender-dependent differences in Cushing’s disease.
Little is known, however, on molecular features of ACTH-secreting adenomas from female
and male patients, an avenue of research which may yield novel insights into Cushing’s disease
pathophysiology and, possibly, provide the basis for tailored diagnostic and therapeutic approaches.
The aim of the present study was to evaluate differences in ACTH-secreting adenomas collected from
female and male patients. Our approach to gender differences was two-fold, on the one side we
assessed the secretory status of corticotrope adenomas in culture, on the other we compared the gene
expression profile in archival adenomatous specimens.
2. Results
2.1. ACTH Synthesis and Secretion Pattern
Data from 124 adenoma primary cultures was available. Spontaneous ACTH secretion at both
4 h and 24 h was significantly lower in cultures obtained from male compared to female patients
(Table 1). Lower ACTH levels were also observed in cultures from male patients during CRH and
dexamethasone incubation although the percentage change over baseline was comparable (Table 1).
Basal as well as CRH- and dexamethasone-modulated POMC expression was comparable in specimens
from female and male patients (Table 1).
Table 1. Secretory pattern in adenomas from female and male patients with Cushing’s disease.
Parameter Female Patients Male Patients
ACTH 4 h baseline (ng/100,000 cells) 8.26 ± 1.76 3.26 ± 1.69 *
ACTH 4 h DEX (ng/100,000 cells) 7.18 ± 2.03 0.87 ± 0.39 *
ACTH 4 h CRH (ng/100,000 cells) 30.98 ± 8.37 12.79 ± 6.63 *
ACTH 24 h baseline (ng/100,000 cells) 25.35 ± 5.88 7.94 ± 3.61 *
ACTH 24 h DEX (ng/100,000 cells) 16.69 ± 5.02 1.49 ± 0.44 *
ACTH 24 h CRH (ng/100,000 cells) 63.49 ± 14.61 50.42 ± 29.76
ACTH 4 h % change with CRH 395.09 ± 71.11 323.59 ± 98.76
ACTH 24 h % change with DEX 116.18 ± 24.18 114.76 ± 18.59
POMC baseline (relative to RPLP0) 98.2 ± 29.41 74.69 ± 62.93
POMC 24 h CRH (ratio vs. baseline) 1.65 ± 0.16 3.44 ± 1.38
POMC 24 h DEX (ratio vs. baseline) 0.83 ± 0.08 0.67 ± 0.27
* p < 0.05 vs. specimens from female patients.
2.2. USP8 Sequencing
USP8 sequencing was performed in 111 adenoma specimens and 29 proved carriers of somatic
mutations; in detail, 25 adenomas out of 84 specimens tested in culture carried USP8 variants as did 5
out of 38 specimens used in microarray analysis. All variants have been previously described [10,12].
As expected, the proportion of USP8 variant carriers was greater in adenomas from female compared to
male patients (32.2% vs. 4.2%, p < 0.005); in fact, only a single adenoma from a male patient presented
an USP8 mutation (i.e., p.P720R); thus, no subanalysis according to USP8 variant status could be
performed. We present a description of the experimental results and their interpretation, as well as the
experimental conclusions that can be drawn.
2.3. Gene Expression Pattern
To determine the expression pattern common to samples from male or female patients with
Cushing’s disease, we first identified gene expressed in samples (9 males and 31 females) from either
sex: out of 20,815 genes, 2141 and 1914 were significantly expressed in all female and male specimens,
respectively. Analysis of gene lists revealed 1206 genes expressed in both groups, 935 expressed only in
specimens from female patients and 708 only in specimens from male patients. Functional annotation
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in genes expressed in both revealed enrichment in functions related to ribosomal function, protein
biosynthesis, vesicle transport groups, similar to previously described annotations in corticotrope
adenomas per se [13]. Analysis of the two sets of uniquely expressed genes is shown in Tables 2 and 3.
Table 2. Functional annotation of genes expressed uniquely in specimens from male patients with
Cushing’s disease.
Category Term Count p Value
Annotation Cluster 1 Enrichment Score: 2.5871443516464256
UP_KEYWORDS Transit peptide 32 0.0001
UP_SEQ_FEATURE transit peptide:Mitochondrion 30 0.0002
GOTERM_CC_DIRECT GO:0005743~mitochondrial inner membrane 26 0.0021
GOTERM_CC_DIRECT GO:0005759~mitochondrial matrix 20 0.0054
UP_KEYWORDS Mitochondrion 45 0.0165
GOTERM_CC_DIRECT GO:0005739~mitochondrion 51 0.0670
Annotation Cluster 2 Enrichment Score: 1.5413963866565796
UP_KEYWORDS Iron-sulfur 7 0.0067
UP_KEYWORDS 4Fe-4S 5 0.0196
GOTERM_MF_DIRECT GO:0051539~4 iron, 4 sulfur cluster binding 5 0.0406
UP_KEYWORDS Iron 14 0.1282
Annotation Cluster 3 Enrichment Score: 1.535426320231244
UP_KEYWORDS Iron-sulfur 7 0.0067
GOTERM_MF_DIRECT GO:0051537~2 iron, 2 sulfur cluster binding 4 0.0412
UP_KEYWORDS 2Fe-2S 3 0.0899
Annotation Cluster 4 Enrichment Score: 1.384474121480598
GOTERM_CC_DIRECT GO:0005913~cell-cell adherens junction 18 0.0202
GOTERM_MF_DIRECT GO:0098641~cadherin binding involved in cell-cell adhesion 16 0.0374
GOTERM_BP_DIRECT GO:0098609~cell-cell adhesion 14 0.0931
Annotation Cluster 5 Enrichment Score: 1.340383397277057
GOTERM_BP_DIRECT GO:0006362~transcription elongation from RNA polymerase Ipromoter 5 0.0144
GOTERM_BP_DIRECT GO:0045815~positive regulation of gene expression, epigenetic 6 0.0469
GOTERM_BP_DIRECT GO:0006363~termination of RNA polymerase I transcription 4 0.0745
GOTERM_BP_DIRECT GO:0006361~transcription initiation from RNA polymerase Ipromoter 4 0.0864
Table 3. Functional annotation of genes expressed uniquely in specimens from female patients with
Cushing’s disease.
Category Term Count p Value
Annotation Cluster 1 Enrichment Score: 4.211755780679299
GOTERM_MF_DIRECT GO:0098641~cadherin binding involved in cell-cell adhesion 29 0.0000
GOTERM_BP_DIRECT GO:0098609~cell-cell adhesion 27 0.0001
GOTERM_CC_DIRECT GO:0005913~cell-cell adherens junction 29 0.0001
Annotation Cluster 2 Enrichment Score: 3.9643562287208445
GOTERM_BP_DIRECT GO:0000398~mRNA splicing, via spliceosome 28 0.0000
UP_KEYWORDS mRNA splicing 27 0.0000
UP_KEYWORDS Spliceosome 17 0.0000
UP_KEYWORDS mRNA processing 30 0.0000
GOTERM_CC_DIRECT GO:0071013~catalytic step 2 spliceosome 14 0.0001
GOTERM_BP_DIRECT GO:0008380~RNA splicing 18 0.0006
GOTERM_CC_DIRECT GO:0005681~spliceosomal complex 11 0.0045
KEGG_PATHWAY hsa03040:Spliceosome 11 0.0847
Annotation Cluster 3 Enrichment Score: 3.2395038273067827
UP_KEYWORDS Mitochondrion 77 0.0000
UP_SEQ_FEATURE transit peptide: Mitochondrion 34 0.0011
UP_KEYWORDS Transit peptide 34 0.0034
GOTERM_CC_DIRECT GO:0005759~mitochondrial matrix 19 0.1097
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Table 3. Cont.
Category Term Count p Value
Annotation Cluster 4 Enrichment Score: 2.823640223068603
UP_KEYWORDS Ribonucleoprotein 30 0.0000
UP_KEYWORDS Ribosomal protein 20 0.0001
GOTERM_BP_DIRECT GO:0006412~translation 24 0.0004
GOTERM_MF_DIRECT GO:0003735~structural constituent of ribosome 22 0.0004
GOTERM_CC_DIRECT GO:0005840~ribosome 18 0.0004
GOTERM_BP_DIRECT GO:0000184~nuclear-transcribed mRNA catabolic process,nonsense-mediated decay 15 0.0004
KEGG_PATHWAY hsa03010:Ribosome 16 0.0014
GOTERM_BP_DIRECT GO:0006614~SRP-dependent cotranslational protein targeting tomembrane 12 0.0018
GOTERM_BP_DIRECT GO:0019083~viral transcription 12 0.0068
GOTERM_BP_DIRECT GO:0006364~rRNA processing 18 0.0080
GOTERM_BP_DIRECT GO:0006413~translational initiation 12 0.0275
GOTERM_CC_DIRECT GO:0022625~cytosolic large ribosomal subunit 7 0.0557
GOTERM_CC_DIRECT GO:0022627~cytosolic small ribosomal subunit 4 0.3048
Annotation Cluster 5 Enrichment Score: 2.56685352683656
UP_KEYWORDS Nucleotide-binding 96 0.0003
UP_KEYWORDS ATP-binding 77 0.0005
UP_SEQ_FEATURE nucleotide phosphate-binding region:ATP 55 0.0064
GOTERM_MF_DIRECT GO:0005524~ATP binding 82 0.0072
UP_KEYWORDS Kinase 39 0.0257
Annotation Cluster 6 Enrichment Score: 1.9383888797605597
INTERPRO IPR000089:Biotin/lipoyl attachment 4 0.0062
INTERPRO IPR011053:Single hybrid motif 4 0.0082
UP_KEYWORDS Lipoyl 3 0.0128
INTERPRO IPR003016:2-oxo acid dehydrogenase, lipoyl-binding site 3 0.0147
GOTERM_BP_DIRECT GO:0046487~glyoxylate metabolic process 5 0.0213
Annotation Cluster 7 Enrichment Score: 1.818526737361256
GOTERM_MF_DIRECT GO:0019888~protein phosphatase regulator activity 7 0.0010
GOTERM_MF_DIRECT GO:0008601~protein phosphatase type 2A regulator activity 6 0.0014
GOTERM_MF_DIRECT GO:0051721~protein phosphatase 2A binding 5 0.0240
GOTERM_CC_DIRECT GO:0000159~protein phosphatase type 2A complex 4 0.0445
GOTERM_BP_DIRECT GO:0050790~regulation of catalytic activity 4 0.5201
Annotation Cluster 8 Enrichment Score: 1.8075356513460852
KEGG_PATHWAY hsa04728:Dopaminergic synapse 16 0.0007
KEGG_PATHWAY hsa04261:Adrenergic signaling in cardiomyocytes 12 0.0521
KEGG_PATHWAY hsa04071:Sphingolipid signaling pathway 10 0.0998
Annotation Cluster 9 Enrichment Score: 1.4944394402931314
INTERPRO IPR025995:RNA binding activity-knot of a chromodomain 3 0.0215
INTERPRO IPR016197:Chromo domain-like 5 0.0374
GOTERM_BP_DIRECT GO:0016575~histone deacetylation 6 0.0410
Annotation Cluster 10 Enrichment Score: 1.3698761413023455
GOTERM_MF_DIRECT GO:0044183~protein binding involved in protein folding 4 0.0183
INTERPRO IPR027413:GroEL-like equatorial domain 4 0.0201
GOTERM_BP_DIRECT GO:1904874~positive regulation of telomerase RNA localizationto Cajal body 4 0.0223
INTERPRO IPR027409:GroEL-like apical domain 4 0.0241
INTERPRO IPR002423:Chaperonin Cpn60/TCP-1 4 0.0241
GOTERM_BP_DIRECT GO:1904871~positive regulation of protein localization to Cajalbody 3 0.0408
INTERPRO IPR002194:Chaperonin TCP-1, conserved site 3 0.0476
GOTERM_CC_DIRECT GO:0005832~chaperonin-containing T-complex 3 0.0483
INTERPRO IPR027410:TCP-1-like chaperonin intermediate domain 3 0.0806
INTERPRO IPR017998:Chaperone tailless complex polypeptide 1 (TCP-1) 3 0.0806
GOTERM_MF_DIRECT GO:0051082~unfolded protein binding 9 0.0861
GOTERM_BP_DIRECT GO:0032212~positive regulation of telomere maintenance viatelomerase 4 0.1459
Annotation Cluster 11 Enrichment Score: 1.3267539609067143
GOTERM_BP_DIRECT GO:0042752~regulation of circadian rhythm 7 0.0153
UP_KEYWORDS Biological rhythms 11 0.0184
GOTERM_BP_DIRECT GO:0032922~circadian regulation of gene expression 6 0.0870
GOTERM_BP_DIRECT GO:0043153~entrainment of circadian clock by photoperiod 3 0.2007
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Table 3. Cont.
Category Term Count p Value
Annotation Cluster 12 Enrichment Score: 1.3244168484975751
UP_KEYWORDS Glycogen metabolism 5 0.0148
UP_KEYWORDS Carbohydrate metabolism 8 0.0611
GOTERM_BP_DIRECT GO:0005977~glycogen metabolic process 4 0.1174
Annotation Cluster 13 Enrichment Score: 1.322070667802913
UP_SEQ_FEATURE domain:Leucine-zipper 11 0.0118
SMART SM00338:BRLZ 6 0.0390
INTERPRO IPR004827:Basic-leucine zipper domain 6 0.0636
UP_SEQ_FEATURE DNA-binding region:Basic motif 10 0.1765
Annotation Cluster 14 Enrichment Score: 1.302497203152933
UP_SEQ_FEATURE repeat:WD 5 17 0.0212
UP_SEQ_FEATURE repeat:WD 7 12 0.0315
INTERPRO IPR020472:G-protein beta WD-40 repeat 9 0.0324
UP_SEQ_FEATURE repeat:WD 4 17 0.0380
SMART SM00320:WD40 17 0.0384
INTERPRO IPR017986:WD40-repeat-containing domain 20 0.0388
UP_SEQ_FEATURE repeat:WD 6 14 0.0398
UP_SEQ_FEATURE repeat:WD 3 17 0.0566
UP_KEYWORDS WD repeat 17 0.0616
UP_SEQ_FEATURE repeat:WD 1 17 0.0714
UP_SEQ_FEATURE repeat:WD 2 17 0.0714
INTERPRO IPR001680:WD40 repeat 17 0.0717
INTERPRO IPR015943:WD40/YVTN repeat-like-containing domain 20 0.0725
INTERPRO IPR019775:WD40 repeat, conserved site 11 0.1285
Some functions, e.g., mitochondrion, cell–cell adhesion, RNA transcription, were enriched in
both gene sets, with different genes associated with the same functional pathway. For example, JUP
(junction plakoglobin) and PFN1 (profilin 1) contributed to cell-cell adhesion terms in specimens from
male patients and LIMA1 (LIM domain and acting binding 1) and ADD1 (adducin 1) contributed
to the same term in specimens from female patients. Genes uniquely expressed in female samples
could also be annotated to the spliceosome and ribosome KEGG pathways, nucleotide binding,
chaperonin and histone de-acetylation GOTERM functions and WD-repeats in Uniprot sequence
features. Conversely, in samples from male patients, the iron-sulphur pathway was enriched for
Uniprot and GOTERM databases.
Differential expression analysis identified several genes variably expressed according to
gender. Genome Studio and Limma algorithms yielded comparable results: overall, 31 genes
were overexpressed in samples from male patients and 24 genes in samples from female patients
(Table 4, Figure 1).
Several genes encoded on chromosome Y were overexpressed in samples from male patients, e.g.,
USP9Y, KDM5D, EIF1AY, ZFY, TTTY14, NLGN4Y. Conversely, none of the genes overexpressed in
adenomas collected from female patients are encoded on the X chromosome. Analysis of differently
expressed genes revealed that several genes detected at higher levels in specimens from male or
female patients are known to present tissue-dependent sexual dimorphism, e.g., CALB1, SPP1, PENK.
Among genes overexpressed in samples from male patients a considerable number are associated with
tumourigenesis, e.g, FH, NETO2, NXP2, PDLIM2, PTMA, whereas other genes, such as SOX4 and SPP1,
are involved in pituitary pathophysiology. SSTR5, encoding for the somatostatin receptor subtype
5, was overexpressed in samples from female patients (Table 4). Conversely, the other somatostatin
receptor subtypes were not differentially expressed and mean expression in samples from male and
female patients was comparable (ratio average normalized expression 1.01, 1.02, 0.93 and 0.97 for SSTR1,
SSTR2, SSTR3 and SSTR4, respectively, all diff-scores N.S.). None of the major oestrogen-responsive
genes [14,15] proved to be overexpressed in samples from female patients.
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Table 4. Genes differentially regulated according to sex.
Genes Up-Regulated in Adenomas from Male Patients
SYMBOL DiffScore Chr DEFINITION
B3GALT1 45,498 2 beta 1,3-galactosyltransferase 1
C3 40,959 19 complement component 3
EIF1AY 21,706 Y eukaryotic translation initiation factor 1A, Y-linked
FADS2 52,155 11 fatty acid desaturase 2
FAM174B 19,587 15 family with sequence similarity 174, member B
FGF5 47,607 4 fibroblast growth factor 5
FH 15,527 1 fumarate hydratase
HAPLN3 42,829 15 hyaluronan and proteoglycan link protein 3
ISG20 13,330 15 interferon stimulated exonuclease gene 20 kDa
JAM2 41,419 21 junctional adhesion molecule 2
KDM5D 83,236 Y lysine demethylase 5D (former JARID1D)
MAP4K2 14,458 11 mitogen-activated protein kinase kinase kinase kinase 2
MIR612 49,436 microRNA 612
NETO2 42,006 16 neuropilin (NRP) and tolloid (TLL)-like 2
NLGN4Y 43,635 Y neuroligin 4, Y-linked
NXPH2 51,966 2 neurexophilin 2
PDLIM2 41,894 8 PDZ and LIM domain 2 (mystique)
PENK 40,750 8 proenkephalin
PTMA 13,638 2 prothymosin alpha
SKAP1 14,899 17 src kinase associated phosphoprotein 1
SOX4 51,205 6 SRY (sex determining region Y)-box 4
SPP1 43,227 4 secreted phosphoprotein 1 (osteopontin)
THAP12 14,458 11 THAP domain containing 12 (former PRKRIR)
TMEM97 15,527 17 transmembrane protein 97 (former MAC30)
TMSB4Y 50,840 Y thymosin beta 4, Y-linked
TTTY14 51,522 Y testis-specific transcript, Y-linked 14
TXLNGY 44,773 Y taxilin gamma pseudogene, Y-linked
USP9Y 38,904 Y ubiquitin specific peptidase 9, Y-linked
WFS1 20,982 4 Wolfram syndrome 1 (wolframin)
ZFY 62,438 Y zinc finger protein, Y-linked
ZNF256 13,638 19 zinc finger protein 256
Genes up-regulated in adenomas from female patients
SYMBOL DiffScore Chr DEFINITION
AKAP12 −35,303 6 A kinase anchor protein 12 (gravin)
ANKRD24 −13,814 19 ankyrin repeat domain 24
ATAD2 −20,693 8 ATPase family, AAA domain containing 2
B3GNT7 −13,766 2 eta-1,3-N-acetylglucosaminyltransferase 7
C19orf18 −19,587 19 chromosome 19 open reading frame 18
CALB1 −39,948 8 calbindin 1, 28 kDa
CALY −42,171 10 calcyon neuron specific vesicular protein (former DRD1IP)
COL4A3 −13,394 2 collagen, type IV, alpha 3 (Goodpasture antigen)
CYP3A5 −19,323 7 cytochrome P450, family 3, subfamily A, member 5
DAPL1 −19,323 2 death associated protein-like 1
DNALI1 −38,678 1 dynein, axonemal, light intermediate chain 1
DNM1P46 −20,693 15 dynamin 1 pseudogene 46
DPCD −14,466 8 deleted in mouse model of primary ciliary dyskinesia
DPF1 −14,458 19 double PHD fingers 1
EPOR −20,388 19 erythropoietin receptor
FOXD4 −14,149 9 forkhead box D4
FZD9 −18,458 7 frizzled class receptor 9
KSR1 −27,506 17 kinase suppressor of ras 1
NIM1K −14,149 5 NIM1 serine/threonine-protein kinase
PIGZ −25,072 3 phosphatidylinositol glycan anchor biosynthesis, class Z
RAB11FIP1 −13,097 8 RAB11 family interacting protein 1
SLC9A9 −22,712 3 solute carrier family member 9
SSTR5 −15,488 16 somatostatin receptor 5
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3. Discussion
Since its first description by Harvey Cushing [1], ACTH-secreti adenomas rank among the few
tumours with female preponderance. Indeed, with the notable exception of neoplasias in reproductive
organs only few tumours, e.g., meningiomas, thyroid carcinomas, occur more frequently in women
than in men [16,17]. The issue of gender differences in tumour susceptibility has been the focus of
an increasing number of studies, revealing differences in immune surveilla ce, mutations, epigenetic
patterns and, ultimately, gene expression [18–20].
One major contributor to sexual dimorphism is sex hormone-related pathways; in fact, the role of
oestrogen in female reproductive organs [21,22] and testosterone in prostate cancer [21,23] has been
clearly established, to the point that it represents the basis for target therapy. Oestrogen also has been
implicated in melanoma [24] and papillary thyroid cancer development [25] whereas progesterone
appears to play a role in meningiomas [26], leading to trials with mifepristone, the progesterone
receptor antagonist [27].
As regards the pituitary, prolactin-secreting ade omas can be induced in animals by prolonged
oestrogen treatment [28,29] and prevented by o strogen recep or agonists [30]. In vitro, oestradiol
stimulated both lactotrope, somatotrope and corticotrope proliferation [31,32], while testosterone
appeared to inhibit proliferation in lactotrope and gonadotrope adenomas [31]. Oestrogen receptors
have also been linked to aggressiveness in non-functioning pituitary adenomas [33] and in pancreatic
neuroendocrine tumours [34]. Several studies sought oestrogen receptors by immunohistochemistry
in corticotrope adenomas, but expression appears far less than in other pituitary adenomas [35–37].
Conversely, immunohistochemical analysis revealed that over 50% of corticotrope adenomas and
normal corticotrope cells express the androgen receptor [38].
From a clinical viewpoint, in addition to clear preference for the femal sex [2], clinical presentation
and course differ between men and women with Cushing’s disease. In fact, our first report
on gender-dependent differences among these patients [3] was subsequently confirmed by other
investigators [6–9]. Male patients with Cushing’s disease usually present at a younger age, with more
severe hypercortisolism and pronounced clinical features; hypogonadism induced by cortisol excess
appears an important contributor to some clinical signs in males [8,39,40]. As regards hormonal
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secretion, urinary free cortisol levels are higher in male patients with Cushing’s disease [3,6] as occurs
in normal adult men [41,42]; plasma ACTH concentrations follow the same pattern as higher levels
have been observed in male patients [3,6,7,9], as well as in normal men [42,43]. Comparison of
responses to diagnostic tests revealed that men with Cushing’s disease are less likely to inhibit with the
high dose dexamethasone test [3,7,8] and less likely to present positive pituitary magnetic resonance
imaging [3,6]; in fact, inferior petrosal sinus sampling was required more frequently in men than
women to confirm the pituitary lesion [44]. Of note, a higher prevalence of pituitary macroadenomas
in male patients has been reported in two Chinese series [7,8], thus there might by ethnic diversity
in sexual dimorphism of corticotrope adenoma size. In addition to the more complex diagnostic
work-up, men with Cushing’s disease present less favourable surgical outcomes and higher risk of
recurrence after successful surgery [3,4,8,45]. Control of hypercortisolism by kecotonazole, one of the
mainstays of medical therapy in Cushing’s disease, also proved worse in male compared to female
patients [5]. These abovementioned findings were mostly reported in adults with Cushing’s disease,
as the difference in both prevalence and clinical features was less pronounced in children with pituitary
ACTH-secreting adenomas [46,47], again underlying the potential contribution of sex hormones to
presentation of Cushing’s disease.
Interestingly, exome sequencing recently identified two somatic mutations, i.e., USP8 and USP48,
which occurred with far greater frequency in corticotrope adenomas from women with Cushing’s
disease [10,11], thus indicating that the corticotrope adenoma itself may harbour features which
contribute to gender-dependent differences in Cushing’s disease. In fact, we and others observed
different molecular signatures in adenomas carrying USP8 variants compared to USP8-wildtype
adenomas [12,48,49], and this carried over into increased POMC synthesis and ACTH secretion [12]
and changes in intracellular signalling [50].
Our study aimed to identify differences in cellular and molecular features in adenomas collected
from male and female patients with Cushing’s disease and can indeed report on several, relevant
differences. These results are of major interest given that most studies on corticotrope adenomas were
performed on specimens from women with Cushing’s disease—quite inevitable, given the skewed
gender prevalence—and thus the findings most likely reflect features of female corticotrope adenomas
rather than corticotrope adenomas per se. Of note, only corticotrope adenomas from patients with
features of hypercortisolism were included in the study.
One major finding relates to ACTH secretion as specimens from male patients secreted considerably
less ACTH than their female counterparts. Spontaneous ACTH secretion in adenomas from male
patients was less than half the concentrations measured in adenomas from women at 4 h and nearly
one third at 24 h. Furthermore, corticotrope adenomas from males secreted less ACTH in response to
CRH stimulation compared to females, although the percent change from baseline was comparable
between sexes. In addition, medium ACTH concentrations during incubation with dexamethasone
were tenfold less in corticotrope cultures from male patients compared to female patients. Again,
the percent change from baseline during dexamethasone did not differ between sexes, indicating
proportionality in the response to dexamethasone. These in vitro results are inverse to in vivo findings,
in fact, as mentioned above, ACTH plasma levels are usually higher in men than in women with
Cushing’s disease, and men present a lesser response to dexamethasone inhibition. On the other
hand, plasma ACTH is an unreliable marker of corticotrope tumour activity [42] and, indeed, cortisol
rather than ACTH represents the parameter for diagnosis and treatment monitoring in Cushing’s
disease [51,52]. It follows that only results obtained in corticotrope tumour primary cultures reveal the
secretory features of these adenomas.
As regards ACTH synthesis, we did not observe differences in POMC expression between male-
and female-excised adenomas both in unchallenged wells and after CRH/dexamethasone incubation.
This finding is in line with the lack of correlation between POMC and ACTH in corticotrope adenomas
in vitro [53,54] and, in the present setting, suggests that sexual dimorphism affects POMC peptide
processing and secretion rather than POMC transcription.
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Analysis of gene expression in specimens from female and male patients with Cushing’s disease
revealed some uniquely expressed genes in the context of considerable similarities between the sexes.
In fact, evaluation of significantly expressed genes showed that over 50% of genes were expressed
in both female- and male-derived adenomas and, further, that several uniquely expressed genes
concurred to the same cellular function. For example, both groups were enriched for cell–cell adhesion,
mitochondrion and RNA processing although annotated genes differed. These differences, as well
as gender-distinctive annotations, provide clues as to sexual dimorphism in tumoural susceptibility.
In this context, studies on the role of oestrogen on breast cells illustrated the relationship between
the oestrogen-regulated transcriptome and the mitogenic response [55]. Conversely, the androgen
receptor mediates the angiogenetic and immune response to neoplasia in several tumour models [17,56].
The role of sex hormones on these differences in functional annotations remains to be established.
Differential gene expression analysis proved significant for a small number of genes, 31 and 24
in samples from male and female patients, respectively, approximately 0.2% out of the entire gene
expression set. This percentage is in line with results obtained in normal tissues and blood cells [57–59]
and in some cancers, e.g., colon adenocarcinoma, acute myeloid leukemia [57,60]; conversely, up to
14% of genes were differentially expressed according to sex in other tumours, such as kidney clear cell
carcinoma, thyroid carcinoma, liver hepatocellular carcinoma [57,60], suggesting marked diversity in
sexual dimorphism across neoplasias.
Nearly 30% of genes overexpressed in adenomas from male patients are encoded in the Y
chromosome whereas none of the genes overexpressed in female originate from the X chromosome
(see Table 4). All protein coding genes are X-Y homologues and reside in the AZF locuses [61].
Given that only approximately 4% of genes originate from sex chromosomes, adenomas from male
patients are enriched in genes from the Y chromosome. Several of these genes, e.g., EIF1AY, USP9Y,
ZFY, TMSB4Y, have been used as gender-specific tissue biomarkers for both normal and tumoural
tissues [57,58,62,63]; corticotrope adenomas can now be added to the list of tissues presenting these
markers of sexual dimorphism.
In addition to sex chromosome-encoded genes, several autosomal genes were up-regulated
in adenomas from male patients; of note, PDLIM2, PENK, SOX4, FH, PTMA and TMEM97 are all
associated with tumourigenesis [64–69], and thus could play a role in the less favourable course of
corticotrope adenomas in male patients. Links between these factors and the pituitary are known for
PTMA and SOX4, as PTMA nuclear staining has been linked to pituitary tumour size [70], and SOX4 is
involved in pituitary development, as shown in both zebrafish [71] and human tissues [72]. Along
the same line, another gene overexpressed in male-derived adenomas associated with the pituitary
is SPP1 (osteopontin) with increased expression reported in ACTH-secreting adenomas compared
to non tumourous pituitary tissue [73] and in corticotrope and lactotrope adenomas compared to
other pituitary tumours [49]. Interestingly, SPP1 is known to present sexual dimorphism as greater
expression was observed in male compared to female rat pituitaries [74] and oestrogens have been
shown to modulate SPP1 expression in a variety of tissues [75,76]. Another gene of interest is PENK,
i.e., proenkephalin, part of the POMC-derived opioid family [77]. In addition to the abovementioned
role in tumourigenesis [68], there is evidence for its modulation by glucocorticoids [78], gender-distinct
expression [79] and involvement in the hypothalamo-pituitary-adrenal axis [80].
On the other hand, among genes overexpressed in adenomas from female patients, AKAP12
(gravin) is a known tumour suppressor [81] and SLC9A9 is associated with epidermal growth factor
(EGF) receptor turnover [82], EGF itself notably involved in corticotrope tumourigenesis [83,84].
Overexpression of FZD9, a receptor to Wnt proteins, further links adenomas from female patients with
EGF, as the EGFR pathway interacts with Wnt/ßcatenin signalling [85]. Another gene overexpressed in
samples from female patients is EPOR, i.e., the erythropoietin receptor; given that erythropoietin has
been shown to modulate ACTH intracellular concentration and secretion in AtT 20 cells [86]; this finding
could contribute to the gender-dependent difference ACTH secretion by corticotrope adenoma primary
cultures. Interestingly, somatostatin receptor subtype 5 was also among genes expressed with greater
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abundance in adenomas from female patients. Assessment of somatostatin receptor in corticotrope
adenomas had revealed that SSTR5 is the most abundant receptor isoform [87,88]. Interest in SSTR5
rests on the fact that that pasireotide, a somatostatin analogue with affinity for several somatostatin
receptor subtypes including SSTR5, is being used to contain tumoural corticotrope secretion. Clinical
efficacy of subcutaneous pasireotide is possibly superior in women [89], but gender-skewed sample
collection—the vast majority of samples were from female donors—might have influenced this result.
Overexpression of SSTR5 has recently been reported among USP8-mutated corticotrope adenomas
compared to wild-type adenomas [49]; however, USP8 mutations were found in adenomas from
female patients only, thus this finding could be gender- rather than USP8-variant specific. In fact,
findings reported so far on USP8 variant adenomas [12,48–50] were collected almost exclusively in
female patients; only two specimens were obtained from male patients, the remainder (80 USP8 variant
adenomas in the four series) in female patients. A multicentre effort is clearly required to discern
sex-independent, USP8-determined features.
Furthermore, among genes overexpressed in female samples is calbindin (CALB1), a calcium-
binding protein expressed within the brain with known sexual dimorphism [90]. In fact, oestrogen and
androgen treatment or receptor blockade are known to affect calbindin expression in the preoptic area,
cortex and cerebellum [90]. Calbindin is expressed in the mouse developing pituitary and appears to
localize mainly in corticotropes and somatotropes [91]; in adult rats, calbindin staining was stronger in
somatotrope cells from male animals and corticotrope and lactotrope cells from female animals [92],
suggesting gender-dependent differences in calcium signalling. Further to genes overexpressed
in specimens from female patients is CYP3A5, encoding for one of the major drug-metabolizing
cytochromes [93]. CYP3A5 is induced by corticosteroids in the liver and can both induce drug
resistance and activate prodrugs; it is the subject of ongoing studies in several neoplasias [93] and
could represent a viable drug target for corticotrope adenomas from female patients. Interestingly,
CYP3A5 together with CALB1, DAPL1 and FZD9 were recently reported to be enriched in human
ACTH-secreting adenomas compared to other pituitary adenomas [49]. Given our findings, these
results are likely to reflect predominance of female specimens in the series (22 vs. 5 from men) in lieu
of lineage-specific features.
4. Materials and Methods
4.1. Specimens
One hundred fifty-three ACTH-secreting pituitary adenomas were collected during
transsphenoidal surgery for Cushing’s disease. All tumours fulfilled criteria for “corticotrope adenoma”
(8272/0) according to WHO 2017 Classification of Pituitary Tumours [94]; null cell and silent corticotrope
adenomas were not included. The diagnosis of Cushing’s disease had been established by standard
criteria [51,95]. Our specimen collection comprised 31 men and 122 women, aged from 14 to 76 years
(median 40.1 years). No significant differences as regards surgical outcome and adenoma size were
detected between sexes; men were slightly older than women (see Table 5). Presurgical medical
treatment was reported in 12 (4 men) out of 117 patients in whom this information could be established;
six patients had been treated with ketoconazole, five with cabergoline and one patient with s.c.
pasireotide; all drugs had been interrupted at least 3 days prior to surgery. MIB-1 staining was <2% in
all but one specimen; this adenoma presented MIB-1 index 9%, mitosis count 3 per 10 high power field
and had been collected from a female patient in whom surgery proved successful. As per our previous
publications [53,96,97], the presence of corticotrope cells in fresh adenoma specimens was assured by
abundant ACTH secretion in culture medium [98]; as regards formalin-fixed specimens, abundant
POMC and absent GH, PRL, PIT1, LHB, FSHB expression was documented by microarray analysis [13].
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Table 5. Features of female and male patients with Cushing’s disease.
Parameter Female Patients (n = 122) Male Patients (n = 31)
age (years) 38.9 ± 1.27 44.0 ± 2.89 *
microadenoma (% entire series) 56.3% 50%
invasiveness (% entire series) 9.8% 12.5%
surgical remission (% entire series) 69.2% 67.0%
recurrence (% remission series) 4.1% 3.2%
ACTH staining (% cells) 87.2 ± 1.36 87.1 ± 2.07
* p < 0.05 vs. specimens from female patients.
4.2. Human Pituitary Adenoma Primary Culture
Specimens were established in culture according to our standard protocol [98,99]; primary cultures
were incubated in serum-free DMEM + 0.1% bovine serum albumin (BSA) containing 10 nM CRH or
10 nM dexamethasone. Wells treated with DMEM + BSA only represented control secretion. Medium
was collected after 4 h and 24 h for measurement of ACTH; after 24 h, RNA was extracted using Pure
Link RNA mini kit (Invitrogen, Carlsbad, CA, USA).
4.3. ACTH Assay
ACTH was measured by immunometric assay (Diasorin S.p.A. Saluggia, Italy) with all samples
from a given specimen assayed in the same run. Intra-assay coefficient of variation is 7.9% and assay
sensitivity 1.2 pg/mL. Given the considerable variability in ACTH adenoma concentrations [98], ACTH
concentrations were normalized to number of cells per well and responses to CRH and dexamethasone
expressed relative percent of secretion in wells incubated with DMEM + BSA only (control = 100%) for
statistical analyses. Plated cells counts were comparable between specimens from female and male
patients (138,305 ± 18,460 vs. 110,449 ± 23,372 cells per well, respectively, N.S.)
4.4. Microarray Analysis from Archival Specimens
RNA was extracted from formalin-fixed paraffin-embedded adenomatous samples using
Recover All Total Nucleic Acid Isolation Kit (Life Technologies, Carlsbad, CA, USA), as previously
described [12,13]. RNA (300 ng) was analysed on Human HT_12 v4 Bead Chip (Whole Genome
DASL High Throughput assay, Illumina, San Diego, CA, USA) and fluorescence data captured
into HiScan, a high-resolution laser imager (Illumina). Array data has been deposited at https:
//www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=itsvwwkuzjyvpsj&acc=GSE93825.
4.5. Differential Gene Expression Analysis
Two approaches were used to identify differences in gene expression patterns. First, we identified
the expression pattern common to adenomas from either sex. Genome studio software (Illumina) was
used to identify genes significantly expressed, i.e., detection p value < 0.01, in all specimens from either
male or female patients and the two lists were compared for genes expressed in both or either group.
Second, differential expression across all probes was analysed by Genome Studio and Limma [100].
Expression was analysed after quantile normalization and genes with Benjamini-Hochberg p < 0.05
were considered significant. Diff Scores were calculated based on p value transformation according to
the difference between average signals in specimens from male and female patients with Cushing’s
disease. Volcano plot [101] was used to illustrate differential expression.
4.6. Functional Annotation and Gene Ontology
DAVID v6.7 [102] was used to annotate and classify significant genes and perform functional
annotation clustering. Minimum value of enrichment score for significant clusters was 1.3. Clusters
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were annotated to Gene Ontology (GO) project, Kyoto Encyclopedia of Genes and Genomes (KEGG)
and Protein Information Resource (SP_PIR).
4.7. USP8 Sequencing
RNA was obtained from formalin-fixed or fresh specimens and carried out as previously
described [12,103].
4.8. Real-Time PCR
RNA (100 ng) was reverse transcribed (Superscript-Vilo cDNA synthesis kit; Life Technologies) and
quantitative Real-Time PCR performed on 7900 HT sequence Detection System (Applied Biosystem,
Foster City, CA, USA), using Platinum Quantitative PCR Supermix-UDG with premixed ROX.
Taqman assay (Applied Biosystem) was used for POMC quantification (probe Hs00174947_m1). Basal
expression data (2−∆Ct) was calculated and normalized to RPLP0 (probe Hs99999902_m1); expression
after treatments was analysed as 2−∆∆Ct and expressed in fold change from baseline [53].
4.9. Ethics
The study was conducted in accordance with the Declaration of Helsinski and the protocol
approved by the Ethical Committee of the Istituto Auxologico Italiano (protocol 02C102_2011 approved
on 12/04/2011 and protocol 02C402_2014 approved on 4/3/2014). Informed consent for the use of
secondary surgical materials was granted by patients prior to surgery.
4.10. Statistical Analysis
Differences between specimens from female and male patients with Cushing’s disease were
established by ANOVA, Mann-Whitney test, chi-square test or Fisher’s exact test, as appropriate, using
Statview 4.5 (Abacus Concepts, Berkeley CA, USA). Significance was accepted for p < 0.05 and data is
given as mean ± S.E.M.
5. Conclusions
In conclusion, our study is the first to report on sexual dimorphism in molecular and
cellular features in human ACTH-secreting pituitary adenomas and provides the basis for novel,
gender-dependent perspective on the pathophysiology of Cushing’s disease. Future studies
on corticotrope tumours have to take sexual dimorphism into account and, possibly, identify
gender-tailored therapeutic approaches.
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